Factors Associated with Risk of Recurrent Transient Global Amnesia
JAMA Neurol 77:1551-1558, Morris, K.A.,et al, 2020
Transient Global Amnesia After Sildenafil (Viagra) Use
Neurol 59:778, Savitz,S.A.&Caplan,L.R., 2002
Transient Global Amnesia:Clinical Characteristics & Prognosis
Neurol 37:733-737, Miller,J.W.,et al, 1987
Transient Global Amnesia, Recurrences are Rare and Patients May Drive
BMJ 302:62-63, Cartlidge,N.E.F., 1991
Single Photon Emission Computed Tomography in Cerebrovascular Disease
Stroke 22:950-954, Fayad,P.B.&Brass,L.M., 1991
The Transient Global Amnesia-Migraine Connection
Arch Neurol 41:75-79, Crowell,G.F.,et al, 1984
Transient Global Amnesia & Migraine
Neurol 31:1167-1170, Caplan,L.,et al, 1981
Migraine
NEJM 377:553-561, Charles, A., 2017
Stroke-Like Migraine Attacks after Radiation Therapy (SMART) Syndrome is not Always Completely Reversible: A Case Series
AJNR 34:2298-2303, Black, D.F.,et al, 2013
SMART Syndrome (Stroke-Like Migraine Attacks After Radiation Therapy) in Adult and Pediatric Patients
J Child Neurol 29:336-341, Armstrong, A.E.,et al, 2013
Neurological Complications of Sclerotherapy for Varicose Veins
J Vasc Surg 55:243-251, Sarvananthan, T.,et al, 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Headache in Transplant Patients
www.medlink.com, Aug, Lai, T.H., 2011
SMART Syndrome: A Late Reversible Complication after Radiation Therapy for Brain Tumours
J Neurol 258:1098-1104, Kerklaan, J.P.,et al, 2011
Hemorrhagic Manifestations of Reversible Cerebral Vasoconstriction Syndrome: Frequency, Features, and Risk Factors
Stroke 41:2505-2511, 2455, Ducros,A.,et al, 2010
Central Anticholinergic Syndrome on Therapeutic Doses of Cyproheptadine
Pediatrics 103:158-160, Watemberg,N.M.,et al, 1999
Neurologic Disorders in Renal Failure (1st of Two Parts)
NEJM 294:143, Raskin,N.H.,et al, 1976
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Cyclic Vomiting Syndrome in Children
AJGH 2:doi:10.33552/AJGH.2020, Al-Ansari, N., 2020
Encephalopathy in a Large Cohort of British Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Patients
Stroke 50:283-290, Drazyk, A.M.,et al, 2019
A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age with Epilepsy
JAMA Neurol 76:783-790, Kim, H.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Treatment Effects and Comorbid Diseases in 58 Patients with Visual Snow
Neurol 93:e398-e403, vanDongen, R.M.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
Migraine and Risk of Perioperative Ischemic Stroke and Hospital Readmission: Hospital Based Registry Study
BMJ 356:e6635, Timm. F.P.,et al, 2017
Clinicopathologic Conference, MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke like episodes)
NEJM 376:1668-1678, CASE 13-2017, 2017
Intravenous Immune Globulin: Adverse Effects
UptoDate June, Perez, E.E. & Silvergleid, A.J., 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Acute Headache Diagnosis in Pregnant Women
Neurol 85:1024-1030, Robbins, M.S.,et al, 2015
Evidence-Based Treatments for Adults with Migraine
Pain Reser Treat 2015:DOI:10.1155/2015/629382, Gooriah, R.,et al, 2015
Transient Ischemic Attack Requiring Hospitalization of Children in the United States
Stroke 45:887-888, Adil, M.M.,et al, 2014
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
Stroke and NonStroke Brain Attacks in Children
Neurol 82:1434-1440, Mackay, M.T.,et al, 2014
Young Patient with Headache and Amaurosis Fugax
Stroke 45:e3-e4, Saarela, M.,et al, 2013
Positive Persistent Visual Symptoms (Visual Snow) Presenting as a Migraine Variant in a 12-Year-Old Girl
Pediatr Neurol 49:361-363, Simpson, J.C.,et al, 2013